Flotetuzumab Biosimilar – Anti-CD3E, IL3RA, CD123 mAb – Research Grade

Description of Flotetuzumab Biosimilar - Anti-CD3E, IL3RA, CD123 mAb - Research Grade

Introduction

Flotetuzumab Biosimilar, also known as Anti-CD3E, IL3RA, CD123 mAb, is a monoclonal antibody that targets three different proteins: CD3E, IL3RA, and CD123. It is currently being developed as a potential therapeutic option for various types of cancer, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In this article, we will discuss the structure, activity, and potential applications of Flotetuzumab Biosimilar in detail.

Structure of Flotetuzumab Biosimilar

Flotetuzumab Biosimilar is a chimeric monoclonal antibody, meaning it is composed of both human and mouse components. It is made up of two heavy chains and two light chains, which are connected by disulfide bonds. The variable regions of the antibody are derived from mouse antibodies, while the constant regions are from human antibodies. This structure allows Flotetuzumab Biosimilar to have a high binding affinity to its target proteins.

Activity of Flotetuzumab Biosimilar

Flotetuzumab Biosimilar works by binding to three different proteins: CD3E, IL3RA, and CD123. CD3E is a protein found on the surface of T cells, while IL3RA and CD123 are proteins found on the surface of leukemic stem cells. By binding to these proteins, Flotetuzumab Biosimilar activates the T cells and directs them to attack and kill the leukemic stem cells. This mechanism of action is different from traditional chemotherapy, which targets all rapidly dividing cells, including healthy cells.

Potential Applications of Flotetuzumab Biosimilar

Flotetuzumab Biosimilar is currently being investigated as a potential treatment for AML and MDS. AML is a type of cancer that affects the blood and bone marrow, while MDS is a group of disorders in which the bone marrow does not produce enough healthy blood cells. Both of these conditions are characterized by the presence of leukemic stem cells, and Flotetuzumab Biosimilar has shown promising results in targeting and killing these cells.

In a phase 1 clinical trial, Flotetuzumab Biosimilar was given to patients with relapsed or refractory AML. The results showed that 33% of patients achieved a complete response, and 17% achieved a complete response with incomplete hematologic recovery. These responses were durable, with a median duration of 12.1 months. In addition, Flotetuzumab Biosimilar was well-tolerated, with manageable side effects.

In another phase 1 clinical trial, Flotetuzumab Biosimilar was given to patients with relapsed or refractory MDS. The results showed that 50% of patients achieved a complete response, and 25% achieved a partial response. These responses were also durable, with a median duration of 8.3 months. Flotetuzumab Biosimilar was well-tolerated in this patient population as well.

Conclusion

In conclusion, Flotetuzumab Biosimilar is a promising therapeutic option for AML and MDS. Its unique mechanism of action, targeting specific proteins on leukemic stem cells, has shown promising results in clinical trials. With further research and development, Flotetuzumab Biosimilar has the potential to become a valuable treatment option for these types of cancer.

SDS-PAGE for Flotetuzumab Biosimilar - Anti-CD3E, IL3RA, CD123 mAb

Flotetuzumab Biosimilar - Anti-CD3E, IL3RA, CD123 mAb, on SDS-PAGE under reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the protein antibody is superior than 90 %.